These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: Depletion of T-lymphocytes in donor marrow with pan-T monoclonal antibodies and complement for prevention of acute graft-versus-host disease: a pilot study on 29 patients. Author: Herve P. Journal: J Natl Cancer Inst; 1986 Jun; 76(6):1311-6. PubMed ID: 3520074. Abstract: A cooperative study was done on ex vivo treatment of bone marrow for the prevention of acute graft-versus-host disease (GvHD), in which either CD2-CD5-CD7 (14 patients) or CD2-CD3 (15 patients) monoclonal antibody cocktail and complement were used. In this study, 29 patients (12 female, 17 male; average age, 22-1/2 yr) received T-cell-depleted allograft through complement cytolysis, 26 from HLA-identical donors and 3 from HLA-mismatched donors. All of the patients had malignant disease with poor prognosis; 21 had acute leukemia, 7 had chronic granulocytic leukemia, and 1 had multiple myeloma. After bone marrow transplantation (BMT), GvHD prophylaxis was maintained in 12 patients (group 1), was stopped at day 11 in 6 patients (group 2), and was not administered to 11 patients (group 3). The treatment removed 92.65 +/- 5.36% of donor bone marrow T-cells with one round of complement lysis. Of 3 patients who received mismatched transplant, 2 did not achieve engraftment. Engraftment was achieved in all of the patients who had matched BMT. Two patients had acute GvHD, 1 with grade 2 in group 1, and 1 with grade 3 in group 3. No patient has developed chronic GvHD; for 9 patients, the follow-up is longer than 6 months. Five patients relapsed within 6 months after BMT. Eighteen patients are alive and well in complete remission, with an average follow-up of 7.5, 10.6, and 2.7 months for patients in groups 1, 2, and 3, respectively.[Abstract] [Full Text] [Related] [New Search]